Abstract-Inherited epidermolysis bullosa (EB) is a heterogeneous group of rare genodermatoses with a high skin fragility manifested by the formation of destructive blisters and non-healing erosions on the skin and mucous membranes as a reaction to minor mechanical influences. There are three main types of EB: simple, junctional and dystrophic, each is caused by mutations in genes that encode epidermal, zones of the basement membrane or dermis proteins, respectively. The fourth type of EB is also described -hemidesmosomal or Kindler syndrome with impairments in kindlin-1 protein encoded by the FERMT1 gene. The existing ways to improve the living conditions of patients with EB are at different stages of development: some of them are already used in the clinic, while others are still under laboratory research. Various strategies are used, depending on the type of EB and the nature of mutation inheritance: from the functional gene replacement therapy based on the viral expression to the genome editing methods by programmable synthetic nucleases. The accumulated experience of allogeneic and autologous transplants of skin equivalents opens the prospect for using new approaches to functional gene and cell therapy ex vivo.
Inherited epidermolysis bullosa (EB) is a heterogeneous group of rare genodermatoses. It is characterized by increased sensitivity for mechanical impact. Clinical manifestations of EB are blisters and erosions of both skin and mucous membranes. Such lesions may appear after a minor injury or even in normal condition. These symptoms occur due to defects in genes of structural skin proteins. These proteins provide intraepidermal (or dermo-epidermal junctions) [1] . The main types of EB include epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), and dystrophic epidermolysis bullosa (DEB). The DEB is subdivided into dominant DEB (DDEB) and recessive DBE (RDEB). Kindler syndrome is also recognized as a separate type of EB [2] .
Genes with mutations responsible for the acquisition of the EB phenotype were identified for each type of EB. At present, at least 18 genes of structural skin proteins and more than 1000 their mutations are known to be associated with EB [3] [4] [5] . The damage to the COL7A1 gene encoding collagen type VII (C7) is the cause of both DEB forms. In case of JEB -there are mutations in genes which are involved in the formation of laminin 322 and integrin α6β4, as well as the COL17A1 gene mutation. The most cases of EBS are determined by damages of genes KRT5 and KRT14 genes, as well as PLEC gene.
There is no effective therapy for patients with EB due to the genetic nature of the disease [6] . Although, recent studies demonstrate the promising methods for effective and affordable treatment of EB in the future [7] . The main research options for therapy of EB can be divided into two groups of strategies-ex vivo and in vivo. This review focuses on the methods of the ex vivo strategy, based on a combination of both gene and cell therapies. This strategy includes three main stages. The first one is the cultivation of primary cell lines derived from a patient's biopsy specimens. The second stage is the genome editing of cultured cells. And third one is the autologous transplantation of the transgenic skin equivalent. An important issue for the successful functional therapy is the presence of epidermal stem cells in the primary cultures, as the genome editing of these cells is crucial for securing the long-term therapeutic effect from autologous transplantation. The induced pluripotent stem cells (iPSCs) obtained from a patient's somatic differentiated skin cells provide an unlimited capability for subsequent genetic modification, differentiation, and supplementation of the genetically edited cells population. The ex vivo gene 1 The article was translated by the authors. therapy of EB patients can be performed using various methods. The most promising among them are gene replacement by transduction, editing of genes by programmable nucleases, and RNA therapy. Correction of mutations involves the delivery of an exogenous gene-modifying cassette to target cells. The low efficiency of delivering genetic material to cells is an important factor which at present limits the effectiveness of ex vivo functional therapy methods. Methods can be divided into groups according to the process of delivery. The two main groups are viral systems and non-viral artificial vector systems.
VIRAL STRATEGIES
Historically, the gene replacement method was the first one used [7, 8] . In this case, the transduction was performed by retrovirus MLV (Mouse Leukemia Virus). The expression of the target gene was under the control of viral LTRs (Long Terminal Repeats) promoter. In the first work of this paper cycle, a patient with JEB had a heterozygous mutation in the LAMB3 gene, which encoded one subunit of heterotrimeric laminin 332. The mutation resulted in the lack of expression of this protein which lead to disruption of both the dermal-epidermal junction and the structure of the basement membrane components. Cells from the patient's skin biopsy, the epidermal stem cells and keratinocytes, were cultured. Gene replacement technique was performed by retroviral transduction. Vector contained a full-length copy of cDNA (complementary DNA) of the LAMB3 gene. The transduced cells were cultured in vitro to form the epidermal layer. The resulting autologous skin equivalent was transplanted to the patient. The subsequent analysis of patient's tissues showed the expression of laminin 332 and the restoration of the adhesive properties of cells in the area of transplantation. Observation of the patient for 6 years showed no symptoms of JEB. No erosions or blisters were observed on the skin. There were no inflammation and no immune response to the transplant. Later an important achievement in the field of functional therapy of EB was made in the laboratory of Michele de Luca [9] . A 7-year-old boy suffering from JEB was given a series of autologous transplantations. The skin equivalents consisted mainly of keratinocytes after transduction. The retroviral vector with LAMB3 cDNA was the same as described above. Almost the entire surface of the child's skin was transplanted (0.85 m 2 ). During 3 years, the expression of laminin was maintained in transplanted keratinocytes. No pathological blisters were detected on the skin over the entire surface of the patient's body. Taken together, these works on functional JEB therapy showed that genome editing in autologous keratinocytes (containing the epidermal stem cells) makes it possible to obtain long-lived, functional, and selfrenewing transgenic epidermis after skin equivalent transplantation. Such transplants can eliminate the clinical manifestations of JEB for at least several years.
Unfortunately, the gene replacement strategy with retroviral transduction did not produce such a positive effect in the case of functional therapy of DEB. Four patients suffered from severe RDEB, accompanied by the absence of type VII collagen synthesis. They were subjected to autologous transplantation of transgenic skin equivalents [8] . The retroviral vector contained a full-size copy of the COL7A1 cDNA. The synthesis and secretion of full-length type VII collagen was restored in transplanted keratinocytes. C7 is the result of a series of post-translational modifications, secretion, and subsequent processing in the extracellular matrix. In human skin, C7 forms the basis of the fibrillary part of the extracellular matrix of the dermis (the anchoring fibrils of the papillary dermis). In the skin of patients with RDEB, the anchoring fibrils are not formed, the structure of the dermo-epidermal junction is disturbed, and blisters appear. The formation of anchoring fibrils was observed after transplantation of transgenic epidermis in the skin of patients with RDEB. The wounds and blisters disappeared in the areas of transplantation. Tissues became more resistant to mechanical stress. However, the effect was temporary. The protein expression decreased in a 6 months after post-transplantation period. A year later, symptoms of the disease returned in all patients.
Such different effects of gene replacement therapy revealed the need to analyse the factors that determine the mechanisms of transplantation effectiveness maintainance. Siprashvili et al. suggested that differences in transplantation efficacy in the case of JEB and RDEB could be could be accounted for different amounts of epidermal stem cells in the transplants. It is supported by the fact of the acute deficiency of epidermal stem cells in patients with DEB [8] . The insufficient number of stem cells available for transplants is the factor which limits the success of the gene therapy not only of keratinocytes but also of allogeneic bone marrow transplants [10] . The secretion of laminin 332 affects the cells that produce it. It stimulates their adhesion and creates an advantage for growth of transplanted cells. In the case of RDEB therapy, the transplanted cells restore the secretion of the structural protein C7. C7 is indirectly connected to the system of growth factors, but transplanted cells do not receive any advantages in growth. The gene replacement therapy investigations focused on the targeted expression of the corrected gene and the functionality of the transgenic protein product was not evaluated. Experimental data on retroviral gene therapy indicate the need to study this issue prior to introduction of biomedical cell product into clinical practice. Lentiviruses capable of infecting both dividing and nondividing cells are also used for the gene therapy of EB.
The use of vectors based on retroviruses could potentiate tumor formation. Retroviruses integrate into actively transcribed DNA regions. Changes in the expression and activation of unknown promoter regions could occur in the transduced cells as the result. In spite of these possible drawbacks there were no cases of an immune response to transplantation and no oncological transformations were found after the restoration of damaged protein functions in patients with EB. This fact led to the success of this therapeutic gene replacement strategy in clinical practice.
Viral Systems, which Are Not Integrated
This approach is based on the adeno-associated viral vectors (AAV-Adeno-Associated Viruses). The risk of mutagenesis mediated by the accidental incorporation of certain elements into the genome is reduced with AAV-based transgenesis. The AAV virus system based on serotypes 2, 6, and 8 is used for efficient transfection of primary human keratinocytes [11] . For example, AAV transduction was used for gene therapy of EBS. The mutations in KRT14 were corrected, which causes a severe form of EBS (the Dowling-Meara subtype). The transduction of epidermal stem cells of the patient by AAV serotype 6 was performed. The missense mutation of dominant-negative type in KRT14 determine the replacement of arginine 125 by cysteine in cytokeratin 14. In such cases, a knockout of the mutant allele in the patient's cells can lead to the emergence of protein with normal function due to the activity of another, not mutated, allele.
For gene targeting the cDNA of green fluorescent protein gene was placed under the control of IRES (Internal Ribosome Entry Site) and inserted into the 3rd exon of KRT14 gene. Transduced cells were separated by fluorescence-activated cell sorting (FACS). The green fluorescence revealed the process of insertion and destruction of the reading frame of the mutant KRT14 gene. The resulting clones had the "off" expression of the KRT14 mutant allele [12] . Transplantations of the gene edited skin equivalents to immune-deficient mice were successful. Further studies demonstrated that the transplanted epidermal layers had the normal structure. The authors note that the skin equivalent, obtained from a single cell, contained 10 13 cells. This fact emphasizes the possibility of using the proliferative potential of a single stem cell to produce a functional epidermal equivalent which is sufficient for transplantations for the large skin surfaces.
The successful use of vectors based on AAV for functional therapy of DEB was demonstrated by Chamorro et al. In this work, a specific mutation in the COL7A1 gene was corrected in the keratinocytes of the patient [13] . AAV-based vector system is used as donor template for homologous recombination in gene correction (see below). Single-stranded DNA molecules are synthesized in a cell as a result of viral transduction and the efficiency of homologous recombination with this type of molecule increases [14] . An interesting methodological approach to the gene therapy of the LAMA3 gene using AAV is presented in the article by Melo et al. [15] . A new AAV serotype with a high recombination activity (AAV-DJ) was obtained. It facilitates an effective gene editing in keratinocytes. The AAV vector contained a wild-type LAMA3 gene fragment with exons 43 and 44. The mutant allele of this gene in a child with JEB contained a reading frame failure due to preliminary termination codon (PTC) in exon 45. Degradation of mRNA of the mutant LAMA3 gene resulted in the absence of laminin protein in the cells. NMD (Nonsense-Mediated Decay) system in living cells recognizes and degrades mRNA molecules that carry PTCs. In this case, an open reading frame was restored when expressed from the viral cassette. The appearance of non-mutant LAMA3 and the synthesis of functional laminin-α3 (the subunit of heterotrimeric laminin 332) was observed after homologous recombination. An important feature of this work was the perfect strategy of functional positive selection and production of target cells. The cells acquired the ability to adhere and to grow due to the restored function of laminin 332. Viral strategies for gene therapy have benefits associated with the good efficiency of genetic material delivery into cells and the ability to infect different types of cells, but they have a significant limitation in the capacity of vectors (it is not possible to clone long inserts). This makes impossible their use for cloning big inserts containing long DNA sequences.
NON-VIRAL GENE THERAPY STRATEGIES
The main advantage of transfections with non-viral vectors is a safer integration profile, low toxicity, and low immunogenicity [16] . Yet, the efficiency of exogenous genetic cassette delivery into cells is limited by transfection efficiency. For such cells as human keratinocytes, transfection efficiency is often low. This disadvantage is overcome by the selection of transfected cells with additional tools. To that end, fluorescent marker genes or antibiotic resistance genes are inserted into plasmids, which carry fragments of the sequence from the corrected genes without mutations. After the transfection clones are selected using FACS or by their growth capacity on a selective medium.
As the new period in gene therapy started-the usage of programmable synthetic nucleases for genome editing-the increase in the of transient transfection efficiency started to be the important stage of this procedure, as it promotes the delivery of nuclease system into cells. The creation of transgenic cell lines with constant expression was no more such an urgent task [17] . 
Genome Editing Strategies
The area of functional gene therapy started to develop rapidly advancement with the appearance of technologies of direct genome interference. The activity of synthetic nucleases can be specifically "programmed" or directed to an irreversible change in the nucleotide sequence of a gene in the region of a mutation (target DNA). Furthermore, a directional change in the sequence could be achieved without the integration of proviral or any other additional sequences. The most used synthetic nucleases for genome editing are zinc finger domains (ZFN-Zinc Finger Nuclease), TALEN (Transcription Activator-Like Effector Nucleases-effector nucleases similar to transcriptional activators), CRISPR/Cas systems (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-ASsociated protein). They allow to knock out the target gene or replace it in order to restore the function of the protein [18] . The main advantages of this technology is the ability to target this system to any sequence in the genome while preserving endogenous promoters for gene expression.
TALEN are the chimeric proteins that include the nuclease domain and the DNA binding TALE domain. TALE domain is the transcription factor derived from a plant pathogen. Each DNA-binding domain consists of 35 amino acid residues repeats arranged in tandem. Each such repeat in turn recognizes only one nucleotide in the DNA major groove. Thus, the TALE-domain set recognizes a unique DNA sequence of 20 nucleotides in length. This synthetic system is able to recognize specifically any DNA sequence. The disadvantages of TALEN domains are the laboriousness and complexity of their cloning. If it is necessary to replace one sequence for editing into another one the design of TALE domain should be changed completely and the entire chimeric TALEN should be cloned [19, 20] .
In contrast to the functioning of TALEN proteins, the action of the CRISPR/Cas system is directed by non-coding RNA. CRISPR are short palindromic repeats, regularly arranged in groups and separated by unique sequences (spacers). Cas is a nuclease that cuts foreign DNA. The specificity of such cutting is determined by short non-coding RNAs that recognize and bind the target DNA sequence. The name of the system reflects its prokaryotic origin. It is the part of the immune system of prokaryotes, which includes several similar families. The most widely used protein today is Cas9 (or spCas9, as the protein is isolated from Streptococcus pyogenes). CRISP/Cas9 belongs to type II CRISPR systems. In this system CRISPR segments are transcribed, processed and, combined with transactivating RNA (crRNA/tracrRNA), form the socalled guide RNA. Guide RNA interacts complementary with the target DNA fragment and recognizes the target DNA. After binding to DNA, these RNAs interact with Cas9-nuclease. Cas9-nuclease, which rearranges its conformation and is activated to cut DNA [21] . A necessary element of the system is the presence of a three-nucleotide PAM motif in DNA (Protospacer Adjacent Motive). PAM has a 5'-NGG-3' structure, where N is any nucleotide. PAM should be located in the DNA next to the recognition site of the guide RNA. Activated Cas9 cuts DNA approximately 4 nucleotides from PAM, forming a double-stranded break. The CRISPR/Cas9 nuclease system does not require de novo protein design for recognition of each new target. It is only necessary to select a sequence containing PAM and to synthesize the specific guide RNA.
The important feature and the disadvantage of the CRISPR/Cas system is its non-target activity. The guide RNA can nonspecifically anneal which causes the cutting of another sequence, which is often located in another gene, on a different chromosome. This activity could cause the lethal changes in the physiology of an edited cell [22] . Several dozens of programs and online resources exist, which predict the efficiency, specificity, and nonspecific activity of the guide RNAs [23] . After the editing is performed the main task is to select cells with desired changes but not cells with nonspecific mutations in other sequences [20] . Edited cells could be used for creation the transgenic epidermal cellular equivalents suitable for autologous transplantation into patients only after the whole genome sequencing tests be performed.
Besides Cas9, different mutant variants of this protein are used in genome editing: Cas9n D10A [24] ; BE-HF1,2,4; Fok1-dCas9; espCas9 [25] ; Hypa-Cas9 [26] . Also, there are other systems. For example, Cpf1 (CRISPR/Cas12, a V-type system isolated from Streptococcus aureus) uses different PAM nucleotide sequence.
The mechanism of synthetic nucleases action is essentially the induction of double-stranded breaks in genomic DNA. Those breaks are then repaired in the cell using mainly two different mechanisms: NonHomologous End Joining (NHEJ) and HomologyDirected Repair (HDR) [17] . NHEJ leads to the accumulation of insertions and deletions in the cell, and frequently to a failure of the reading frame. This is the easiest and most effective way to edit a gene. Mutations in different loci of an allele can be turned off by running a single programmed nuclease. This repair path often creates knockout mutants of the target gene [19] . HDR leads to the replacement of a mutant DNA sequence by a wild-type sequence. The frequency of spontaneous HDR in cells is significantly lower than NHEJ. HDR takes place in cells only at certain stages of the cell cycle: at the end of the S-phase and in the G2-phase. This is the reason why the efficiency of mutation correction using HDR is low. The process of mutation correction requires the presence of an exogenous donor DNA sequence in the cell. Also, significant quantities of donor DNA is needed. The donor DNA can be in the form of a single-stranded DNA fragment or in the form of plasmid DNA. The donor plasmid DNA should contain the corrected sequence surrounded by so-called "homology arms" (from 200 to 1000 nucleotides).
The first work on TALEN-mediated gene editing was performed using the cells of a patient diagnosed with RDEB. The PTC in the COL7A1 gene was eliminated by HDR [27] . C7 expression appeared in the patient's fibroblasts after genomic editing. As the primary cells have a limited lifespan the authors obtained isogenic iPSCs after genetic correction. Then the edited iPSCs were checked in mice. They obtained skin teratoma models from the edited iPSCs. Both NHEJ and HDR were used for the correction of PTC in the following work on the editing of the COL7A1 gene. This work was already mentioned above when the AAV system was described [13] . The studied c6527insC mutation is often found in Spanish patients with a diagnosis of RDEB and leads to the emergence of PTCs. The AAV system was used for the delivery of the nuclease system TALEN and donor DNA. Using HDR individual clones were obtained with C7 expression at the physiological level. The action of TALEN on genomic DNA without a donor sequence led to the formation of a set of deletions and insertions. In several cases, the violation of the reading frame occured. As a result, several clones with a restored open reading frame of COL7A1 were found and selected. In both cases (NHEJ-and HDR-mediated repair), C7 synthesis and the formation of structures similar to human anchoring fibrils were detected after transplantation of transgenic epidermal skin equivalents to immunodeficient mice.
In the work of Shinkuma et al. gene editing was used for knockout of a heterozygous mutation in exon 109 COL7A1 that cause DDEB [28] . This mutation resulted in a 15 bp deletion. The resulting product was translated in the COL7A1 reading frame and formed the non-functional C7 trimer. Editing was performed on iPSCs derived from mutant human primary fibroblasts. The COL7A1 gene fragment was edited by means of the NHEJ using TALEN nuclease and in parallel using the CRISPR/Cas9 system. It turned out that the CRISPR/Cas9 system performs editing approximately 2-3 times more efficiently. Therefore, later on, only CRISPR/Cas9 was used for work with iPSCs. A plasmid mixture was used during transfection of iPSCs. The first one encoded spCas9. The second-encoded guide RNA. Each plasmid contained cDNA of one of the fluorescent reporter genes. One with emission in the green and another in the red region of the spectrum for subsequent selection of transfected cells on a FACS. Four clones with mutations shifting the reading frame of the mutant allele were selected. This mutation led to the emergence of PTC. It was expected that mRNA would degrade due to the work of the NMD mechanism. However, the amount of mRNA did not decrease. A shortened protein was synthesized. A similar phenomenon was described earlier for another mutation with the appearance of PTC in the COL7A1 gene. PTC also does not lead to the degradation of mRNA due to unknown reason [29] . The shortened protein which was obtained as a result of genomic editing did not interact with the normal C7 protein. It was not capable for trimerization. Therefore, this product was less toxic for the cell than the original variant of the C7 protein, which carried the DDEB mutation. The authors noted the advantages of using iPSCs for editing the genome of the cells of patients with DEB. iPSCs have unlimited potential for division and selfrenewal. It is important when building up the cell mass from single edited cells. iPSCs can be differentiated into different cell types. In this case, it is important to get both fibroblasts and keratinocytes from the edited iPSC. Both of them are able to produce and secrete C7 protein and are needed for reconstruction of the skin equivalent. This work demonstrated that it is possible to restore the production of the functional C7 protein in cells by gene knockout using specific nucleases and highly efficient NHEJ. A similar method for editing of iPSCs genome using CRISPR/Cas9 is described in works with RDEB [30, 31] .
Programmable nucleases were used for gene therapy of other types of EB. In particular for editing of dominant-negative mutations in cytokeratins 14 and 5 in EBS cells. In the first work, an improved version of Cas9-Cas9D10A (nickase) was used for correction of mutation in exon 6 KRT14 gene [12, 24] . In the second work, the editing was performed with TALEN domains on the KRT5 matrix in order to create cell lines that carry EBS mutations for their subsequent correction [19] .
In the latter work, a deletion of the mutant allele of the KRT5 gene was also obtained. The editing was carried out on the immortalized cells of the patient. The normal architecture of the cytokeratin network has recovered in the cells as a result of editing and deletion of the dominant negative mutant allele. The intracellular aggregates observed in the patient with EBS disappeared. They managed to directionally insert the PTC in the 5'-region of the coding part of the gene using this editing strategy. The emergence of PTC caused the degradation of the edited gene mRNA due to the NMD mechanism. The cell population after editing was a mixture of both edited and wild-type clones. It was necessary to select the cells with the mutant allele knocked out from the mixture. This was carried out using biochemical and functional analysis. Cells with the normal structure of the cytokeratin network were selected.
In the work of Kocher et al. Cas9D10A (nickase) was used to edit the EBS mutation in KRT14 [24] . An important advantage of nickase is its reduced non-target activity. The mutation in exon 6 of KRT14 occurs with a high frequency and causes the generalized severe EBS. Nickase was specifically directed to intron 7. An intact copy of the gene was inserted and the function of KRT14 was restored as a result of subsequent HDR.
RNA Therapy
A specificity of the approaches, united by the term RNA therapy, is that mutation correction occurs only at the mRNA level. The function of a damaged mutant protein is restored using the mechanisms underlying RNA processing and splicing.
The first technique is based on the use of antisense oligonucleotides for the specific deactivation of an exon. The therapy of RDEB when exons of the COL7A1 gene are turned off is the example. The effectiveness of this approach was shown when disabling a number of exons (70, 73, 80, and 105) of the COL7A1 gene was performed. An increase in the expression of COL7A1 in the basement membrane zone was observed during cell transplantation into mice [32] . It is necessary to note that only exons that are in the same reading frame can be turned off. It limits the use of this method. Antisense oligonucleotides are used successfully in the clinic, and often for functional therapy in vivo. It involves introducing of therapeutic agents directly into the patient's body in order to correct splicing in all organs and tissues.
The second method, SMaRT technology (Spliceosome-Mediated RNA Trans-splicing) uses RNA splicing. Instead of the usual cis-splicing, when joining exons belong to one pre-mRNA molecule, transsplicing occurs in these cases. The trans-splicing permits the connection of exons belonging to different pre-mRNA molecules. Thus, exons without mutation could be connected by replacing parts of the premRNA sequence, which carry the mutations, with their wild-type copies. The wild-type copies are introduced into the cell in the form of exogenous plasmids encoding a part of the pre-mRNA. The elements necessary for splicing are introduced as well: a branch point, a poly-pyrimidine tract, and a "binding domain." A "binding domain" is a fragment that inhibits a competing cis-splicing process. It specifically binds to the endogenous pre-mRNA sequence in the exon-intron region.
RNA-trans-splicing as a therapeutic strategy is applied and passes the stage of preclinical trials in mice for proteins of PLEC, KRT14, COL17A1, and COL7A1 genes [33] . The first successful application of the therapy for correction of mutations in EB using trans-splicing was editing the mutation of the PLEC1 gene [34] . The mRNA of this gene contains 14.2 thousand nucleotides, being one of the longest which greatly complicates the efficiency of cloning and transfection. One of the advantages of trans-splicing is the possibility to use the shorter sequence. Only the cDNA fragment could be used in the vector for the delivery instead of a full-size copy of the cDNA. The trans-splicing plasmid contained a fragment of the 5'-coding part of the PLEC1 gene. It was capable to correct all mutations that could be encountered in this gene region. An important useful feature of the SMaRT technology is the possibility to use the same vector for the correction of different mutations, localized in a given region of a gene. This favorably distinguishes the SMaRT approach from the programmable nuclease method, where the correction of each mutation requires an individual approach. Also, the development of special therapeutic approaches for each case individually is rather expensive due to the multiplicity of EB mutations. The advantages of the transsplicing method as well as methods of genome editing consist in the preservation of endogenous control of gene expression after mutation correction. A significant limitation of SMaRT is the low efficiency of the trans-splicing process itself. It combines with the possible low efficiency of transfection of cells. SMaRT is successfully used for the treatment of recessive mutations when even small amounts of a functional protein which appear in the cell can significantly reduce toxicity and correct cell-cell interactions.
Thus, EB is a heterogeneous group of genodermatoses. It is divided into subtypes depending on the location of the lesion, its severity, proteins involved in the pathogenesis, and type of mutation. In recent years, significant progress has been made in the development of ex vivo functional therapy methods. It brings us closer to the development of the of personalized medicine concept. In addition to virus-based gene replacement therapy, the use of programmable synthetic nucleases aiming to correct mutations in autologous human cells is promising. The combination of genome editing and autologous transplantation techniques leads to the emergence of new biomedical cell products. Some methods are already used in clinical practice. Others have a large potential for development, but still, require further study before they can be introduced into the clinic.
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